Cargando…

Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection

SARS-CoV and SARS-CoV-2 encode spike proteins that bind human ACE2 on the cell surface to enter target cells during infection. A small fraction of humans encode variants of ACE2, thus altering the biochemical properties at the protein interaction interface. These and other ACE2 coding mutants can re...

Descripción completa

Detalles Bibliográficos
Autores principales: Shukla, Nidhi, Roelle, Sarah M., Suzart, Vinicius G., Bruchez, Anna M., Matreyek, Kenneth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284657/
https://www.ncbi.nlm.nih.gov/pubmed/34270613
http://dx.doi.org/10.1371/journal.ppat.1009715
_version_ 1783723430467600384
author Shukla, Nidhi
Roelle, Sarah M.
Suzart, Vinicius G.
Bruchez, Anna M.
Matreyek, Kenneth A.
author_facet Shukla, Nidhi
Roelle, Sarah M.
Suzart, Vinicius G.
Bruchez, Anna M.
Matreyek, Kenneth A.
author_sort Shukla, Nidhi
collection PubMed
description SARS-CoV and SARS-CoV-2 encode spike proteins that bind human ACE2 on the cell surface to enter target cells during infection. A small fraction of humans encode variants of ACE2, thus altering the biochemical properties at the protein interaction interface. These and other ACE2 coding mutants can reveal how the spike proteins of each virus may differentially engage the ACE2 protein surface during infection. We created an engineered HEK 293T cell line for facile stable transgenic modification, and expressed the major human ACE2 allele or 28 of its missense mutants, 24 of which are possible through single nucleotide changes from the human reference sequence. Infection with SARS-CoV or SARS-CoV-2 spike pseudotyped lentiviruses revealed that high ACE2 cell-surface expression could mask the effects of impaired binding during infection. Drastically reducing ACE2 cell surface expression revealed a range of infection efficiencies across the panel of mutants. Our infection results revealed a non-linear relationship between soluble SARS-CoV-2 RBD binding to ACE2 and pseudovirus infection, supporting a major role for binding avidity during entry. While ACE2 mutants D355N, R357A, and R357T abrogated entry by both SARS-CoV and SARS-CoV-2 spike proteins, the Y41A mutant inhibited SARS-CoV entry much more than SARS-CoV-2, suggesting differential utilization of the ACE2 side-chains within the largely overlapping interaction surfaces utilized by the two CoV spike proteins. These effects correlated well with cytopathic effects observed during SARS-CoV-2 replication in ACE2-mutant cells. The panel of ACE2 mutants also revealed altered ACE2 surface dependencies by the N501Y spike variant, including a near-complete utilization of the K353D ACE2 variant, despite decreased infection mediated by the parental SARS-CoV-2 spike. Our results clarify the relationship between ACE2 abundance, binding, and infection, for various SARS-like coronavirus spike proteins and their mutants, and inform our understanding for how changes to ACE2 sequence may correspond with different susceptibilities to infection.
format Online
Article
Text
id pubmed-8284657
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-82846572021-07-28 Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection Shukla, Nidhi Roelle, Sarah M. Suzart, Vinicius G. Bruchez, Anna M. Matreyek, Kenneth A. PLoS Pathog Research Article SARS-CoV and SARS-CoV-2 encode spike proteins that bind human ACE2 on the cell surface to enter target cells during infection. A small fraction of humans encode variants of ACE2, thus altering the biochemical properties at the protein interaction interface. These and other ACE2 coding mutants can reveal how the spike proteins of each virus may differentially engage the ACE2 protein surface during infection. We created an engineered HEK 293T cell line for facile stable transgenic modification, and expressed the major human ACE2 allele or 28 of its missense mutants, 24 of which are possible through single nucleotide changes from the human reference sequence. Infection with SARS-CoV or SARS-CoV-2 spike pseudotyped lentiviruses revealed that high ACE2 cell-surface expression could mask the effects of impaired binding during infection. Drastically reducing ACE2 cell surface expression revealed a range of infection efficiencies across the panel of mutants. Our infection results revealed a non-linear relationship between soluble SARS-CoV-2 RBD binding to ACE2 and pseudovirus infection, supporting a major role for binding avidity during entry. While ACE2 mutants D355N, R357A, and R357T abrogated entry by both SARS-CoV and SARS-CoV-2 spike proteins, the Y41A mutant inhibited SARS-CoV entry much more than SARS-CoV-2, suggesting differential utilization of the ACE2 side-chains within the largely overlapping interaction surfaces utilized by the two CoV spike proteins. These effects correlated well with cytopathic effects observed during SARS-CoV-2 replication in ACE2-mutant cells. The panel of ACE2 mutants also revealed altered ACE2 surface dependencies by the N501Y spike variant, including a near-complete utilization of the K353D ACE2 variant, despite decreased infection mediated by the parental SARS-CoV-2 spike. Our results clarify the relationship between ACE2 abundance, binding, and infection, for various SARS-like coronavirus spike proteins and their mutants, and inform our understanding for how changes to ACE2 sequence may correspond with different susceptibilities to infection. Public Library of Science 2021-07-16 /pmc/articles/PMC8284657/ /pubmed/34270613 http://dx.doi.org/10.1371/journal.ppat.1009715 Text en © 2021 Shukla et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Shukla, Nidhi
Roelle, Sarah M.
Suzart, Vinicius G.
Bruchez, Anna M.
Matreyek, Kenneth A.
Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection
title Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection
title_full Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection
title_fullStr Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection
title_full_unstemmed Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection
title_short Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection
title_sort mutants of human ace2 differentially promote sars-cov and sars-cov-2 spike mediated infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284657/
https://www.ncbi.nlm.nih.gov/pubmed/34270613
http://dx.doi.org/10.1371/journal.ppat.1009715
work_keys_str_mv AT shuklanidhi mutantsofhumanace2differentiallypromotesarscovandsarscov2spikemediatedinfection
AT roellesarahm mutantsofhumanace2differentiallypromotesarscovandsarscov2spikemediatedinfection
AT suzartviniciusg mutantsofhumanace2differentiallypromotesarscovandsarscov2spikemediatedinfection
AT bruchezannam mutantsofhumanace2differentiallypromotesarscovandsarscov2spikemediatedinfection
AT matreyekkennetha mutantsofhumanace2differentiallypromotesarscovandsarscov2spikemediatedinfection